High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C

• Main Authors: Andrew Hill (Author), Giten Khwairakpam (Author), James Wang (Author), Sergey Golovin (Author), Julia Dragunova (Author), Rachel Smith (Author), Vicky Houghton-Price (Author), Roxanna Korologou-Linden (Author), Sanjay Nath (Author), Anna Savage (Author), Greg Jefferys (Author)
• Format: Book
• Published: Elsevier, 2017-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: High prices of direct acting antivirals (DAAs) for hepatitis C virus (HCV) can lead to restrictions on access to treatment in high- and middle-income countries. An increasing number of people in these countries are treating their HCV infection with generic drugs produced in India, China,...